JP7164512B2 - Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 - Google Patents

Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 Download PDF

Info

Publication number
JP7164512B2
JP7164512B2 JP2019500245A JP2019500245A JP7164512B2 JP 7164512 B2 JP7164512 B2 JP 7164512B2 JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019500245 A JP2019500245 A JP 2019500245A JP 7164512 B2 JP7164512 B2 JP 7164512B2
Authority
JP
Japan
Prior art keywords
tim
seq
antagonist
set forth
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524701A (ja
JP2019524701A5 (enExample
Inventor
ショーン・ドイル
マーク・ジェイ・セルビー
エリック・チャドウィック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019524701A publication Critical patent/JP2019524701A/ja
Publication of JP2019524701A5 publication Critical patent/JP2019524701A5/ja
Application granted granted Critical
Publication of JP7164512B2 publication Critical patent/JP7164512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019500245A 2016-07-06 2017-07-05 Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 Active JP7164512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359073P 2016-07-06 2016-07-06
US62/359,073 2016-07-06
PCT/US2017/040665 WO2018009507A1 (en) 2016-07-06 2017-07-05 Combination of tim-4 antagonist and methods of use

Publications (3)

Publication Number Publication Date
JP2019524701A JP2019524701A (ja) 2019-09-05
JP2019524701A5 JP2019524701A5 (enExample) 2020-08-13
JP7164512B2 true JP7164512B2 (ja) 2022-11-01

Family

ID=59366515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500245A Active JP7164512B2 (ja) 2016-07-06 2017-07-05 Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法

Country Status (7)

Country Link
US (2) US11306143B2 (enExample)
EP (1) EP3481866B1 (enExample)
JP (1) JP7164512B2 (enExample)
KR (1) KR102602137B1 (enExample)
CN (1) CN109641968B (enExample)
ES (1) ES2992868T3 (enExample)
WO (1) WO2018009507A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20151102T1 (xx) * 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
US11306143B2 (en) 2016-07-06 2022-04-19 Bristol-Myers Squibb Company Combination of TIM-4 antagonist and PD-1 antagonist and methods of use
WO2021064184A1 (en) * 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
US20250177340A1 (en) * 2021-01-29 2025-06-05 Lapix Therapeutics, Inc. Tartaric Acid Analogs and Uses Thereof
CA3228331A1 (en) * 2021-08-10 2023-02-16 Karla FRIETZE Generation and characterization of novel tim-4 binding agents
KR20240046882A (ko) 2021-08-13 2024-04-11 라픽스 테라퓨틱스, 인코포레이티드 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법
CN115957304A (zh) * 2022-10-18 2023-04-14 山东大学 Tim-4调控胆固醇合成中的应用
EP4649098A1 (en) * 2023-01-13 2025-11-19 Shanghai Kaijin Biotechnology , Ltd Multi-specific polypeptide complexes
WO2025077833A1 (en) * 2023-10-11 2025-04-17 Suzhou Neologics Bioscience Co., Ltd. Antibodies targeting tim-3 and pd-1 and uses thereof
CN117904122B (zh) * 2023-12-22 2025-01-28 北京贝来药业有限公司 一种编码抗pd-1抗体的基因及其修饰干细胞的制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP2015209376A (ja) 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CN101035561A (zh) 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
US11306143B2 (en) 2016-07-06 2022-04-19 Bristol-Myers Squibb Company Combination of TIM-4 antagonist and PD-1 antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP2015209376A (ja) 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human Vaccines & Immunotherapeutics，11(10)，2015年，2458-2462

Also Published As

Publication number Publication date
US20190389950A1 (en) 2019-12-26
US11306143B2 (en) 2022-04-19
KR20190026843A (ko) 2019-03-13
EP3481866B1 (en) 2024-07-24
US20220275091A1 (en) 2022-09-01
CN109641968A (zh) 2019-04-16
JP2019524701A (ja) 2019-09-05
WO2018009507A1 (en) 2018-01-11
EP3481866A1 (en) 2019-05-15
ES2992868T3 (en) 2024-12-19
WO2018009507A8 (en) 2019-02-07
KR102602137B1 (ko) 2023-11-13
US12227575B2 (en) 2025-02-18
CN109641968B (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
JP7164512B2 (ja) Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法
US11103579B2 (en) Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
BRPI0607486B1 (pt) Anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
US10983128B2 (en) CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
JP2021528423A (ja) 二重特異性抗ｃｄ３×ｍｕｃ１６抗体および抗ｐｄ−１抗体で癌を治療する方法
CA3026246A1 (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
CA3090177A1 (en) Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
CA3117016A1 (en) Combination therapy for melanoma
JP2021525806A (ja) 疾患または状態を処置するための組成物およびそれらの使用
CA3123873A1 (en) Combination radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
JP2021502416A (ja) ヒトがんの治療のためのモノクローナル抗体ｎｅｏ−２０１
CA3169661A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
JP2022554270A (ja) 抗ｐｄ－１抗体による癌を治療する方法
TW202446792A (zh) 使用可活化抗ｃｔｌａ４抗體與ｐｅｍｂｒｏｌｉｚｕｍａｂ組合治療癌症之方法
AU2023373006A1 (en) Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221020

R150 Certificate of patent or registration of utility model

Ref document number: 7164512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250